← Back to Clinical Trials
Recruiting NCT04940663

NCT04940663 Neurobehavioral Mechanisms of Social Isolation and Loneliness in Serious Mental Illness

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04940663
Status Recruiting
Phase
Sponsor Massachusetts General Hospital
Condition Psychosis
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2022-07-13
Primary Completion 2026-10

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 55 Years
Study Type INTERVENTIONAL
Interventions
EMA

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 120 participants in total. It began in 2022-07-13 with a primary completion date of 2026-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The proposed research will test the hypothesis that objective social isolation and loneliness are linked to neurobehavioral mechanisms involved in social perception and motivation in individuals with and without serious mental illness. Moreover, it will investigate the specific dynamic interactions among these experiences in daily life and how they, and their neurobehavioral predictors, are linked to day-to-day functioning. The findings of this project could provide novel targets for therapeutics aimed at improving functioning and overall quality of life in individuals with serious mental illnesses, as well as quantitative phenotypes for use in early detection efforts.

Eligibility Criteria

Inclusion Criteria: 1. 18-55 years old 2. Experienced a psychotic disorder or mood disorder Exclusion Criteria: 1. Any neurological disorder or current substance use disorder (during the past 6 months) 2. Not proficient in English 3. A recent change in medication, or an acute symptom presentation 4. Standard exclusion criteria for participation in an MRI scan (e.g., presence of metal in the body, claustrophobia, a history of head trauma).

Contact & Investigator

Central Contact

Daphne J Holt, MD, PhD

✉ dholt@partners.org

📞 617-726-7618

Principal Investigator

Daphne J Holt, MD, PhD

PRINCIPAL INVESTIGATOR

Massachusetts General Hospital

Frequently Asked Questions

Who can join the NCT04940663 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Psychosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04940663 currently recruiting?

Yes, NCT04940663 is actively recruiting participants. Contact the research team at dholt@partners.org for enrollment information.

Where is the NCT04940663 trial being conducted?

This trial is being conducted at Charlestown, United States.

Who is sponsoring the NCT04940663 clinical trial?

NCT04940663 is sponsored by Massachusetts General Hospital. The principal investigator is Daphne J Holt, MD, PhD at Massachusetts General Hospital. The trial plans to enroll 120 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology